Thibaut du Fayet
Chief Executive Officer chez PHAXIAM THERAPEUTICS S.A.
Profil
Thibaut du Fayet is currently the Chief Executive Officer at PHAXIAM Therapeutics SA since 2023.
Previously, he worked as the Deputy Chief Executive Officer at Pherecydes Pharma SA in 2022, Director-Marketing & Strategy at bioMérieux SA, Director at Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., and Vice President-Business Development & Marketing at Transgene SA from 2008 to 2013.
He also worked as the Head-Marketing at Stallergenes SA from 2007 to 2008.
Mr. du Fayet holds a graduate degree from Brandeis University and an MBA from ESSEC Business School, which he received in 1992.
Postes actifs de Thibaut du Fayet
Sociétés | Poste | Début |
---|---|---|
PHAXIAM THERAPEUTICS S.A. | Chief Executive Officer | 23/06/2023 |
Anciens postes connus de Thibaut du Fayet
Sociétés | Poste | Fin |
---|---|---|
STALLERGENES | Sales & Marketing | 01/01/2008 |
BIOMÉRIEUX | Sales & Marketing | - |
PHERECYDES PHARMA | Chief Executive Officer | - |
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd.
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China. | Director/Board Member | - |
TRANSGENE | Corporate Officer/Principal | - |
Formation de Thibaut du Fayet
Brandeis University | Graduate Degree |
ESSEC Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
TRANSGENE | Health Technology |
BIOMÉRIEUX | Health Technology |
PHAXIAM THERAPEUTICS S.A. | Health Technology |
Entreprise privées | 3 |
---|---|
Stallergenes SA
Stallergenes SA Pharmaceuticals: MajorHealth Technology Stallergenes SA is an international biopharmaceutical company, which engages in the manufacture and sale of pharmaceutical products for the treatment of allergy-related respiratory diseases. The company operates through the Allergen Immunotherapy segment, which provides products and services for the desensitization of allergy-related respiratory conditions. Its products include a range of sublingual route and subcutaneous route products for the treatment of respiratory diseases such as rhino-conjunctivitis, rhinitis, and allergic asthma. Stallergenes was founded in 1962 and is headquartered in Antony, France. | Health Technology |
Pherecydes Pharma SA
Pherecydes Pharma SA Pharmaceuticals: MajorHealth Technology Pherecydes Pharma SA is a biotechnology company, which engages in the research and development of anti-infective therapies based on the use of bacteriophages. It develops phage treatments of bacterial infections. The company was founded by Jerome Gabard and Manuel Gea in December 2006 and is headquartered in Romainville, France. | Health Technology |
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd.
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China. | Commercial Services |